HCPCS code J0594: Injection, busulfan, 1 mg billing guide

Key takeaways

HCPCS code J0594 covers injection, busulfan, 1 mg, and you bill one unit for every milligram administered.

Medicare Part B pays J0594 at ASP+6% in the physician office, and CMS refreshes that rate every quarter.

A partial vial needs two claim lines: the milligrams administered, then the discarded milligrams with modifier JW.

When nothing is discarded, append JZ instead. A single-dose vial line carrying neither modifier is the most common miss.

Oral busulfan does not belong here. Myleran tablets have their own code, J8510, at 2 mg per unit.

HCPCS code J0594 covers injection, busulfan, 1 mg, the intravenous form of the drug given before a stem cell transplant. The unit is what trips people up.

You bill one unit for every milligram administered, so a 150 mg dose is 150 units, not one vial. On a drug this expensive, a unit error moves thousands of dollars in either direction.

Add the waste modifiers, the NDC on every line, and a diagnosis the payer will accept, and one claim has four ways to fail. We’ll take them in the order a biller works through the claim.

What J0594 covers, and why the unit is one milligram

J0594 describes injection, busulfan, 1 mg. It is a Level II HCPCS J-code maintained by the Centers for Medicare and Medicaid Services (CMS).

J-codes cover drugs a provider injects or infuses. They are billed separately from the service that delivers them, which is why the drug and the infusion appear on different lines.

J0594 sits in the drug section of the Level II set. It follows the same annual update cycle as the rest of the HCPCS codes, and the descriptor has been stable for years. The unit, however, is where claims come apart.

The unit rule that matters most: J0594 is billed per milligram, never per vial. A patient who receives 150 mg generates 150 units on the claim line. Enter one unit per vial and you get paid for a single milligram. Enter the full vial’s 60 units with no waste line, and you get paid for drug the patient never received.

Busulfex bills under J0594, Myleran does not

Busulfan is an alkylating agent. It cross-links DNA strands and stops rapidly dividing cells from replicating. Two formulations reach patients, and only one of them belongs on a J0594 claim.

The IV formulation, Busulfex, is the one J0594 describes. It is used as myeloablative conditioning before hematopoietic stem cell transplantation (HSCT). Most of those patients have chronic myelogenous leukemia (CML) or acute myeloid leukemia (AML), and some have aplastic anemia.

Oral busulfan is a different code entirely. Myleran tablets bill under J8510 at 2 mg per unit, and Medicare handles them through its oral anticancer drug benefit. Coverage there still turns on the indication, so read the payer’s policy rather than assume. What is certain is that oral busulfan never belongs on a J0594 line.

Medicare pays J0594 at ASP+6%, and that rate moves quarterly

Medicare Part B pays provider-administered drugs off the Average Sales Price (ASP). For J0594 in the physician office, that means ASP+6%.

CMS republishes the ASP drug pricing file every quarter, so a figure you noted last quarter may already be stale. Pull the current rate from the CMS Physician Fee Schedule lookup or the quarterly ASP file before the claim goes out.

What the place of service changes

Buy-and-bill is the model in office and outpatient settings. The practice buys Busulfex, administers it, and bills J0594 to recover the acquisition cost plus the 6% add-on. That margin is thin, and it thins further every day a finished claim sits unfiled.

The NDC has to match the vial you opened

Medicare wants a National Drug Code (NDC) on most Part B drug claims, on both the CMS-1500 and the 837P.

It has to be the NDC of the product you administered, not a generic equivalent or a similar package. NDCs change with manufacturing updates, so check the CMS NDC-to-HCPCS crosswalk file each billing cycle.

Reporting format: report the NDC in 11-digit 5-4-2 form, preceded by the N4 qualifier. Follow it with the unit-of-measure qualifier and the quantity administered. Busulfex is a solution, so that quantity is reported in milliliters, even though the claim line units are milligrams. Mixing those two measures up is a quick way to fail a front-end edit.

Because dosing is weight-based, the quantity changes from patient to patient. It has to agree with the dose calculation in the chart. Submit through a clearinghouse that carries the NDC fields on the 837P, then read the acknowledgment rather than assuming the file landed.

The diagnosis has to justify the conditioning regimen

Every J0594 line needs at least one ICD-10-CM code that supports medical necessity. Busulfan has a narrow set of approved indications, and a diagnosis outside them denies on sight.

The pairings below cover most transplant conditioning claims.

Check the payer’s coverage policy before you finalize the pairing. Some Medicare Administrative Contractors (MACs) publish Local Coverage Determinations that narrow the list further.

Keep the oncologist’s order, the transplant protocol, and the diagnosis confirmation in the record, because a post-payment audit will ask for all three.

JW and JZ tell the payer what happened to the rest of the vial

Four modifiers show up on J0594 claims, and two of them decide whether the line reads as complete.

CMS opened voluntary JZ reporting on January 1, 2023, then made it mandatory on July 1, 2023. Since that date, a single-dose vial line carrying neither JW nor JZ looks unfinished to a MAC.

When to use JW, and when to use JZ

Busulfan dosing is weight-based, so a partial vial is the normal case rather than the exception. Say the order is 150 mg and the pharmacy opens three 60 mg vials. That is 180 mg drawn and 30 mg left over.

Two lines go on the claim. The first carries J0594 with 150 units and no waste modifier. The second carries J0594 with modifier JW and 30 units for the discarded milligrams.

JW belongs only on that second line, and both lines carry a charge. Medicare pays for documented waste from a single-dose container, up to the amount on the vial label.

When the whole vial goes into the patient, there is no second line. One line, J0594 with JZ, units equal to the milligrams given. The two modifiers never appear on the same line.

Commercial payers want prior authorization, Medicare usually does not

Traditional Medicare Part B does not normally require prior authorization for J0594 in the physician office.

Commercial plans are another matter. Most large ones, Blue Cross Blue Shield and UnitedHealthcare included, require authorization for Busulfex because of its cost and the regimen it supports.

Start the authorization before the conditioning regimen does. Retroactive appeals on high-cost oncology drugs succeed far less often than a request filed in advance.

Send the transplant protocol, the oncologist’s order naming busulfan as the conditioning agent, the confirmed diagnosis, and the weight-based dose calculation.

Authorization numbers also expire. A conditioning course running across several days can outlive the approval covering it. Put that expiry date somewhere the billing team will see it.

How to bill J0594, step by step

Here is the sequence that keeps a busulfan claim moving. Each step produces something a payer can ask you to hand over later, which is the point of doing them in order.

1. Confirm the code is active. Check J0594 against the current HCPCS annual release or the AAPC HCPCS code lookup. Status changes land with the January update.
2. Pull the NDC. Take it from the CMS crosswalk file, then record the lot number and vial size of the Busulfex you opened.
3. Count the milligrams. Convert the weight-based dose to units, one per milligram, and document the calculation in the chart.
4. Decide the waste. If the full vial went into the patient, append JZ. If any drug was left over, split the claim into an administered line and a JW line for the discard.
5. Point at the diagnosis. Choose the most specific ICD-10-CM code for the malignancy. Add Z94.81 when the encounter is transplant-related.
6. Gather the paperwork. Transplant protocol, oncologist order, authorization approval, administration record. Attach them or keep them ready.
7. File the claim. CMS-1500 for professional billing, UB-04 for facility, 837P for the EDI file. Confirm the clearinghouse acknowledgment.
8. Read the remittance. Watch the 835 for CO-4 (missing or invalid modifier), CO-97 (bundled service), and PR-96 (non-covered charge).

Those eight steps all end up in the same place: one service line. This is what has to be right on it.

Buy-and-bill or specialty pharmacy: who carries the drug cost

Practices reach Busulfex two ways, and the choice decides who fronts the money.

Busulfan is almost always given in a hospital-adjacent or specialized outpatient setting, because the conditioning regimen needs close monitoring. Practices with their own infusion suite tend to buy and bill. That puts the drug on the balance sheet until the claim pays, so the billing calendar and the transplant calendar have to line up.

J0594 rarely travels alone on a transplant claim

Conditioning regimens combine drugs, and each one gets its own J-code line. Knowing what else belongs on the claim stops reimbursable work from going unbilled.

Standard busulfan regimens pair it with cyclophosphamide (Bu/Cy) or fludarabine (Bu/Flu). Cyclophosphamide bills under J9071 through J9075, per milligram, following the April 2024 code changes. Fludarabine bills under J9185. J9062 still turns up in older references, but it is a deleted cisplatin code and does not describe either drug.

The infusion itself is a separate service. Busulfan is an antineoplastic, so administration bills with the chemotherapy codes. That means CPT 96413 for the first hour, 96415 for each additional hour, and 96417 for a sequential infusion of a different drug. The therapeutic infusion codes in the 96365 range are the wrong family here.

Sequencing: on a professional claim, list J0594 against the malignancy as the primary diagnosis. Z94.81 (bone marrow transplant status) or Z51.11 (encounter for antineoplastic chemotherapy) follow as secondary codes. If the transplant admission is inpatient, the conditioning drugs sit inside the MS-DRG and are not billed separately.

Six errors that stall a J0594 claim

Busulfan claims attract attention because they are expensive. These are the denials that show up most often, and each one has a fix that costs less than the appeal would.

• Units counted by vial. J0594 is per milligram administered. Payers run automated edits that compare the unit count against typical dosing for the patient’s weight, so an implausible number gets caught quickly.
• Neither JW nor JZ on a single-dose vial line. Since July 1, 2023 that line reads as incomplete. Build a claim edit that flags any J0594 line missing both.
• A diagnosis outside the covered indications. A generic neoplasm code that does not map to an approved busulfan indication triggers a medical necessity denial. Cross-reference the pairing against the payer’s policy first.
• Authorization missing or expired. For commercial payers, a J0594 claim with no valid authorization number denies immediately. Track expiry dates, not just approvals.
• An NDC that does not match the vial. Transposed digits or a retired NDC delays payment for weeks. Copy the number from the crosswalk file rather than from last month’s claim.
• No transplant protocol on file. Many payers want it on request. Without it, the claim can pay and then be recouped on post-payment audit.

Before you submit: The 60-second check

• Units equal the milligrams in the administration record, not the vials opened.
• Every single-dose vial line carries JW or JZ, and never both.
• The discarded line carries a charge, not a zero.
• The NDC on the claim matches the lot documented in the chart.
• The diagnosis pointer matches the payer’s coverage policy for busulfan.
• The authorization number is on the claim and still valid for this date of service.

When a high-dollar line denies anyway, appeal with the transplant protocol, the administration record, and a letter of medical necessity from the treating oncologist.

That package clears most first-level denials on this code. A repeatable approach to denial management matters more here than on a routine claim. One busulfan line can be worth more than a week of office visits.

How Pabau keeps J-code claims tied to the patient record

Most of what goes wrong on a J0594 claim happens between the infusion suite and the billing queue. The dose lives in the administration record. The code lives in a lookup sheet. Someone retypes one into the other, and the transcription is where the units go astray.

Practice management software like Pabau shortens that trip. Pabau’s claims management software pre-fills the CMS-1500 from the record itself. The code already attached to the service lands on the charge line, and the diagnosis slots are seeded from the patient’s problem list.

ICD-10 and HCPCS lookup libraries sit next to the claim and refresh with each official release, so nobody leaves the screen to confirm a descriptor.

Before a claim can be sent, Pabau checks that the fields the payer requires are complete. On the US pipeline it also runs eligibility checks, tracks claim status, and posts remittances back against the invoice as they return. You still decide which modifier the case calls for. What changes is the number of days a finished claim spends waiting for someone to notice it.

Build the drug claim from the record, not from memory

Pabau pulls the codes and diagnoses already on the patient record straight onto the claim form. Required fields get checked before it can be sent. Your billing team spends less time retyping and more time on the lines that need a decision.

Book a demo

Conclusion

J0594 stops being difficult once the unit logic and the waste rules live in a checklist rather than in one person’s head. The two errors that cost the most, units counted by vial and a missing waste modifier, are both caught before submission or not at all.

The habit worth building is a pre-bill check on every busulfan line, rather than a stronger appeals process. Appeals on this code are winnable. They also tie up weeks of someone’s time chasing money you had already earned.

If your administration records and your claim lines currently sit in different systems, that distance is where the errors come from. Book a demo to see how Pabau builds the claim out of the record your infusion team has already completed.

Continue your research

Need the EDI detail behind a drug claim? 837 electronic claim file walks through the transaction structure that carries NDC and unit data to the payer.

Wondering what your clearinghouse checks first? Medical claims clearinghouse explains the front-end edits that catch a malformed drug line before a payer ever sees it.

Building the charge capture behind the claim? Superbill covers what belongs on the document your billers work from, and what tends to get left off.

Reading remittances line by line? Electronic remittance advice breaks down the 835 and the adjustment reason codes you meet on denied drug lines.

Worried about the audit side of high-value drug claims? Medical billing compliance sets out the documentation habits that hold up in a post-payment review.

Frequently asked questions